Ignite Creation Date:
2024-05-06 @ 7:18 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05964946
Status:
COMPLETED
Last Update Posted:
2023-07-28
First Post:
2023-07-20
Brief Title:
Real-life Study of the Characteristics of Patients Treated With Ilaris Canakinumab for Gouty Arthritis in France
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Real-life Study of the Characteristics of Patients Treated With Ilaris Canakinumab for Gouty Arthritis in France
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a non-interventional retrospective cross-sectional descriptive study conducted on the National Health Data System Système National des Données de Santé SNDS
The study did not modify the doctor-patient relationship nor the management or follow-up of patients Patients with dispensation of canakinumab for gouty arthritis were selected over the period from 08 April 2018 to 07 April 2020 index date was defined as date of the first dispensation of canakinumab in community pharmacy during study period
Patients were described at index date Medical history and comorbidities and previous treatments for gouty arthritis were assessed during 3 years prior to index date Co-treatments of interest for which standard treatments for gouty arthritis were contraindicated or required precautions for use were assessed during 6 months prior to index date
The study did not modify the doctor-patient relationship nor the management or follow-up of patients Patients with dispensation of canakinumab for gouty arthritis were selected over the period from 08 April 2018 to 07 April 2020 index date was defined as date of the first dispensation of canakinumab in community pharmacy during study period
Patients were described at index date Medical history and comorbidities and previous treatments for gouty arthritis were assessed during 3 years prior to index date Co-treatments of interest for which standard treatments for gouty arthritis were contraindicated or required precautions for use were assessed during 6 months prior to index date
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None